secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001171843-24-005618
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus to present imdusiran Phase 2a data in 4 posters at AASLD, including 2 late-breakers
--------------------------------------------------------------------------------

- Four poster presentations at AASLD 2024 (Nov 15-19, San Diego) feature imdusiran, an RNAi therapeutic for chronic HBV.
- Late-breaking posters will show IM-PROVE I and IM-PROVE II Phase 2a trial data.
- Immune biomarker profiling in subjects treated with imdusiran + pegylated interferon reveals phases of immune activation linked to HBsAg seroconversion.
- Imdusiran target site is highly conserved across HBV genotypes A-E; SNPs do not affect HBsAg decline.
- Posters will be available on Arbutus website from November 15, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324005618/0001171843-24-005618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324005618/f8k_101524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-005618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer